幸存者作为多方面的致癌驱动因素和细胞癌的治疗标
Shivani Tuli1, Gabrielle Inserra2, Yamato Murakami3
1Department of Bioengineering, University of Pittsburgh.
bioRxiv : the preprint server for biology
|September 15, 2025
概括
幸存者通过控制细胞分裂和线粒体来驱动侵略性的癌. 抑制生存可能为晚期清细胞细胞癌提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 清细胞细胞癌 (ccRCC) 是一种攻击性的癌症亚型.
- 生存率 (BIRC5) 在RCC中过度表达,并与预后不佳有关.
- 幸存者在癌中的全部作用尚不清楚.
研究的目的:
- 调查幸存者在ccRCC中的功能作用.
- 在先进的ccRCC中分析细胞循环途径失调的转录组数据.
- 探索幸存者对增殖,迁移和线粒体功能的影响.
主要方法:
- 对TCGA-KIRC转录基因组数据的分析.
- 在RENCA细胞中的功能丧失 (siRNA) 和药理抑制 (YM155) 研究.
- 对细胞增殖,细胞循环进展,迁移和线粒体生物能学的评估.
主要成果:
- 先进的ccRCC显示了细胞周期基因的显著失调.
- 抑制生存素减少了ccRCC细胞的增殖,S阶段的进入和迁移.
- 幸存者枯竭改变了线粒体形态和生物能学,表明功能障碍线粒体的清除受损.
结论:
- 幸存者是ccRCC的关键驱动因素,调节细胞周期,迁移和线粒体平衡.
- 幸存者在晚期癌中充当预后生物标志物和治疗标.
- 将生存抑制与代谢或细胞循环疗法相结合可能有利于晚期ccRCC患者.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Retinoblastoma Gene
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K


